VHIO is delighted to announce the candidacy of Josep Tabernero, our Director, for presidency of the European Society for Medical…
Source: Biocat Yesterday, 27 June 2015, the Catalan Ministry of Health and Biocat presented their joint initiative Barcelona Clinical Trials…
Barcelona, May 22, 2015.– Research led by the Vall d’Hebron Institute of Oncology´s Growth Factors Group headed by Joaquín Arribas,…
An international phase III study published in the New England Journal of Medicine (NEJM), in which the Vall d’Hebron University…
Barcelona, 12 May 2015. – VHIO´s César Serrano has been awarded with the 8th Fero Grant for research into the…
VHIO´s 2014 Scientific Report is now available either as a PDF (´light´version), or in its extended version online at: /scientific_reports/en_2014.php. Aside…
Source: American Association for Cancer Research (AACR) PHILADELPHIA — Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies,…
• Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in…
Pancreatic cancer is one of the most aggressive forms of cancer as well as one of the least responsive to…
• The RAISE study, published ahead of print in today´s online version of The Lancet Oncology, is a global Phase…
A vital tool in current armory against cancer is the development of patient-derived tumor xenograft (PDX) mouse models that faithfully…
Incorporating over 20 clinical centers and research entities across 11 countries, including the Catalan Institute of Oncology (ICO) and the…
